People who consume more acesulfame potassium (a diet soda sweetener) are more likely to have clogged arteries and heart disease, according to population studies.
Claim Context
Acesulfame potassium (AceK) is associated with increased risk of coronary heart disease and symptomatic carotid atherosclerosis in observational studies, with elevated plasma levels found in patients with advanced vascular disease.
“A recent cohort study reported that AceK was associated with an increased risk of coronary heart disease, and patients with symptomatic carotid atherosclerosis were found to have elevated plasma levels of AceK and saccharin.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether AceK intake consistently correlates with cardiovascular events across diverse populations.
A systematic review and meta-analysis of 15+ prospective cohort studies with validated dietary assessments and adjudicated cardiovascular endpoints (MI, stroke, death) in adults aged 40–75, stratified by AceK intake levels (low, medium, high).
Whether replacing sugar with AceK-containing beverages directly increases arterial inflammation or plaque formation.
A double-blind RCT of 400 overweight adults with elevated LDL, randomized to daily NSB with AceK (15 mg/kg/day) vs. water or sugar-sweetened beverage for 12 months, measuring carotid intima-media thickness, CRP, and LDL oxidation.
Whether habitual AceK consumption predicts future coronary events.
A prospective cohort of 20,000 adults aged 35–70 with repeated dietary assessments and plasma AceK measurements over 15 years, tracking incidence of myocardial infarction, revascularization, and cardiovascular death.
Whether patients with carotid atherosclerosis have higher prior AceK exposure than healthy controls.
A case-control study comparing 300 patients with symptomatic carotid stenosis (>70%) to 300 matched controls, using 7-day dietary records and plasma AceK levels to estimate 5-year cumulative intake.
A synthesized risk assessment for regulatory bodies.
A consensus panel from EFSA, FDA, and WHO reviewing all human, animal, and mechanistic data to determine if AceK intake warrants a revised ADI or warning label for cardiovascular risk.